The AST/ALT ratio predicts survival and improves oncological therapy decisions in patients with non-small cell lung cancer receiving immunotherapy with or without radiotherapy
The pre-treatment AST/ALT ratio demonstrates potential as a prognostic marker for treatment outcomes in NSCLC patients receiving either ICIs-nonRT or iRT. This finding could help guide clinicians in selecting more effective treatment protocols, thereby enhancing patient prognosis.
Authors
- Yanyan Zhang (ORCID: https://orcid.org/0000-0002-4229-1470)
- Meng Wu (ORCID: https://orcid.org/0000-0003-3213-2967)
- Dawei Chen (ORCID: https://orcid.org/0000-0002-7486-1992)
- Shijie Shang
- Jinming Yu (ORCID: https://orcid.org/0000-0002-8537-839X)
- Jingxin Zhang (ORCID: https://orcid.org/0000-0001-7902-1880)
- Jiachun Ma
- Fei Wang (ORCID: https://orcid.org/0000-0001-9459-9461)
Institutions
- Union Hospital (HK)
- Shandong University (CN)
- Sichuan University (CN)
- Shandong Tumor Hospital (CN)
- Shandong First Medical University (CN)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2024-08-26
- DOI
- https://doi.org/10.3389/fonc.2024.1389804
- Citations
- 8
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- Bethune Charitable Foundation
- National Natural Science Foundation of China
- Chinese Academy of Medical Sciences
- Shandong First Medical University